In contrast to carbamylcholine, which robustly stimulated H508 cell proliferation, both M1R agonists dose-dependently reduced tumor cell proliferation, effects attenuated by pre-incubating cells with a selective M1R inhibitor. This evidence concerns the gene CHRM1 and neoplasm.